# Feng Zhang

Feng Zhang (Chinese: 张锋; pinyin: Zhāng Fēng; born October 22, 1981) is a Chinese-born American biochemist. Zhang currently holds the James and Patricia Poitras Professorship in Neuroscience at the McGovern Institute for Brain Research and in the Departments of Brain and Cognitive Sciences and Biological Engineering at the Massachusetts Institute of Technology. He also has appointments with the Broad Institute of MIT and Harvard (where he is a core member). He is most well known for his central role in the development of optogenetics and CRISPR technologies.

## Early life and education

Zhang was born in China in 1981 and given the name 锋 (which means "point of a spear; edge of a tool; vanguard"). Both of his parents were computer programmers in China. At age 11, he moved to Iowa with his mother (his father was not able to join them for several years). He attended Theodore Roosevelt High School and Central Academy in Des Moines, graduating in 2000. In 1999, he attended the Research Science Institute at MIT, and in 2000 he won 3rd place in the Intel Science Talent Search. He earned his B.A. in chemistry and physics in 2004 from Harvard University, where he worked with Xiaowei Zhuang. He then received his PhD in chemical and biological engineering from Stanford University in 2009 under the guidance of Karl Deisseroth where he developed the technologies behind optogenetics with Edward Boyden. He served as an independent Junior Fellow in the Harvard Society of Fellows.

## Research

Zhang's lab is focused on using synthetic biology to develop technologies for genome and epigenome engineering to study neurobiology. He is a leader in the field of optogenetics, which was named the 2010 "Method of the Year". As a postdoc, he began work on using TAL effectors to control gene transcription.
Based on previous work by the Sylvain Moineau Lab, Zhang began work to harness and optimize the CRISPR system to work in human cells in early 2011. While Zhang's group was optimizing the Cas9 system in human cells, the collaborating groups of Emmanuelle Charpentier and Jennifer Doudna described a chimeric RNA design which is capable of facilitating cleavage of DNA using purified Cas9 protein and a synthetic guide. Zhang's group compared their RNA expression approach with a design based on the Doudna / Charpentier chimeric RNA for use in human cells and established features of the guide necessary for Cas9 to function effectively in mammalian cells which are dispensable in biochemical assays. Zhang, Doudna, and other colleagues from Harvard founded Editas Medicine in September 2013 to develop and commercialize CRISPR-based therapies.
Zhang discovered Cas13 with Harvard colleague Eugene Koonin using computational biology methods. In 2016, Zhang cofounded Arbor Biotechnologies to develop Cas13 for therapeutic use.
His lab has also developed a sensitive diagnostic nucleic acid detection protocol that is based on CRISPR termed SHERLOCK (Specific High sensitivity Enzymatic Reporter UnLOCKing) that is able to detect and distinguish strains of viruses and bacteria present in as low as attomolar (10$^{−18}$ M) concentration. Zhang cofounded Sherlock Biosciences in 2018 to further develop this diagnostic technology.
Also in 2018, Zhang cofounded Beam Therapeutics with Editas cofounder and Harvard colleague David R. Liu to further advance Liu's work on base editing and prime editing.
He has an h-index of 109 according to Google Scholar.

## Honors

Zhang is a recipient of the NIH Director's Pioneer Award and a 2012 Searle Scholar. He was named one of MIT Technology Reviews's TR35 in 2013. His work on optogenetics and CRISPR has been recognized by a number of awards, including: the 2011 Perl-UNC Prize (shared with Boyden and Deisseroth); the 2014 Alan T. Waterman Award, the National Science Foundation's highest honor that annually recognizes an outstanding researcher under the age of 35; the 2014 Gabbay Award (shared with Jennifer Doudna and Emmanuelle Charpentier); the 2014 Young Investigator Award from the Society for Neuroscience (shared with Diana Bautista) as well as the ISTT Young Investigator Award from the International Society for Transgenic Technologies. Zhang also received a New York Stem Cell Foundation (NYSCF) – Robertson Stem Cell Investigator Award in 2014, and was named the 2016 NYSCF – Robertson Stem Cell Prize Recipient.
In 2015, Zhang became the inaugural recipient of Tsuneko & Reiji Okazaki Award (Nagoya University) and in 2016, he was once again (for the 2nd and 3rd time) sharing honors with Doudna and Charpentier when receiving the Gairdner Foundation International Award and the Tang Prize.
In 2016, he became a laureate of the Asian Scientist 100 by the Asian Scientist.
In 2017, he received the Albany Medical Center Prize (jointly with Emmanuelle Charpentier, Jennifer Doudna, Luciano Marraffini, and Francisco Mojica) and the Lemelson-MIT Prize.
In 2018, Zhang was elected as a Fellow of the American Academy of Arts and Sciences, and a member of the National Academy of Sciences, National Academy of Medicine.
In 2019, he received the Harvey Prize of the Technion/Israel for the year 2018 (jointly with Emmanuelle Charpentier and Jennifer Doudna). In the same year, Zhang received the Golden Plate Award of the American Academy of Achievement.
Zhang's research on CRISPR-Cas9 gene editing, while significant, was not recognized by the Nobel Prize committee in 2020, which instead awarded the prize to Emmanuelle Charpentier and Jennifer Doudna for their groundbreaking work on the subject.
In 2021, he received the Richard Lounsbery Award.
In 2025, Zhang and Doudna were both recipients of the National Medal of Technology and Innovation.